Dor Biopharma Cell Thereapeutics
you take one crap company and merge it into another crap company and somehow it turns out 'Magically Delicious"
before you call dor biopharma a crap company look at the unmet medical need and the data from their phase 3 trial
believe me, they don't want ctic stock as consideration but this will get interest in the company now so I am glad the offer was made.
My hope is they raise some money and keep the drug for themselves in the US and just license off the European markets.
What people don't realize is that there are currently 8-10,000 bone stem cell transplants a year. The major reason there aren't more is that there aren't enough matched donors to supply the stem cells for transplant and if you use mismatched donors the death rate is very high
In the Dor phase 3 trial only one of 16 patients with mismatched donors died at 200 days, whereas in the standard of care group I think 12 of 16 mismatched donor transplant recipients died.
If the drug gets approved it will also increase the market size because mismatched donor transplants will be available.
How do you like that for a crappy company
News 
Market Data 
Discover 
